Ocular Therapeutix Inc (NASDAQ:OCUL) Investor Securities Class Action Lawsuit 07/07/2017

If you purchased a significant amount of shares of Ocular Therapeutix Inc (NASDAQ:OCUL) between May 5, 2017 and July 6, 2017, and / or if you purchased any NASDAQ:OCUL shares prior to May 2017 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: September 5, 2017. NASDAQ:OCUL investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Ocular Therapeutix
Case Name: 
Ocular Therapeutix Shareholder Class Action Lawsuit 07/07/2017
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: OCUL
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
07/07/2017
Class Period Begin: 
05/05/2017
Class Period End: 
07/06/2017
Deadline To File for Lead: 
09/05/2017
Summary: 

July 7, 2017 (Shareholders Foundation) - An investor in shares of Ocular Therapeutix Inc (NASDAQ:OCUL) filed a lawsuit over alleged violations of Federal Securities Laws by Ocular Therapeutix Inc in connection with certain allegedly false and misleading statements made between May 5, 2017 and July 6, 2017.

According to the complaint the plaintiff alleges on behalf of purchasers of Ocular Therapeutix Inc (NASDAQ:OCUL) common shares between May 5, 2017 and July 6, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 5, 2017 and July 6, 2017 Ocular Therapeutix issued false and/or misleading statements and/or failed to disclose that Ocular Therapeutix’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product that such manufacturing issues could imperil the approval of DEXTENZA by the FDA, and that as a result, defendants’ public statements were materially false and misleading at all relevant times.

Bedford, MA based Ocular Therapeutix, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.
On May 5, 2017, Ocular Therapeutix Inc disclosed that the U.S. Food and Drug Administration (“FDA”) had found minor issues at its manufacturing plant, but downplayed any concerns.

On July 6, 2017, an article was published asserting that Ocular Therapeutix’s management has been misleading investors about manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix Inc contain bad product.

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) declined on July 7, 2017 to as low as $6.72 per share.